The short-term precision of DXR has previously been determined in

The short-term precision of DXR has previously been determined in 40 pre- and postmenopausal women, demonstrating a coefficient of variance (CV) value of 0.65% [17]. Fig. 1 Principles of digital x-ray radiogrammetry. Using a standard x-ray, the region of interest is automatically detected. From the density curve (right), the external

and internal diameters are detected (117 lines/cm). The reported bone width selleck compound (W), cortical thickness (T) and endosteal diameter are the averages of these measurements. Coefficient of variation (CV) 0.65% Statistical methods Primary analysis of the treatment effect was performed with an ANCOVA model including correction for baseline level and the treatment effect on the logarithmic transformed changes from baseline. Analyses of the influence of gender, height, weight and BMI were made by including them one by one in a repeated measurement ANCOVA model check details with treatment, visit, interaction between treatment and visit and baseline level as fixed effects and subject as a

random effect. The correlations between radiogrammetric and densitometric measurements were estimated in simple linear regression models. Results Baseline demographics Patients (n = 160) were randomised to receive GH (n = 109) or no treatment (n = 51). Baseline patient demographics as well as baseline values for bone parameters by sex and treatment group were not different between groups (Table 1). There were 19 (17.4%) withdrawals in GH-treated patients and 11 (21.6%) withdrawals in the control group. The most common reason for withdrawal from the study was patient decision. Only five patients withdrew due

to adverse events, details of which can be found in the previous publication [13]. Mean GH dose (standard deviation, 2-hydroxyphytanoyl-CoA lyase SD) at study end was 17.9 μg/kg/day (6.3). Table 1 Baseline characteristics of randomised patients by treatment group, mean (SD)   Growth hormone group (n = 109) Control group (n = 51) Male HDAC inhibitors in clinical trials Female Total Male Female Total n (%) 65 (60) 44 (40) 109 (100) 34 (67) 17 (33) 51 (100) Age (years) 21.0 (2.4) 21.2 (2.2) 21.1 (2.3) 21.4 (2.2) 21.4 (2.1) 21.4 (2.1) Height (cm) 172.4 (7.4) 155.8 (7.2) 165.7 (11.0) 170.3 (7.6) 162.1 (8.7) 167.5 (8.8) Weight (kg) 69.6 (13.6) 54.6 (11.1) 63.5 (14.6) 68.5 (13.0) 59.6 (10.7) 65.5 (12.9) BMI (kg/cm2) 23.3 (3.5) 22.4 (3.4) 22.9 (3.5) 23.5 (3.6) 22.6 (3.3) 23.2 (3.5) Bone width (cm) 0.820 (0.076) 0.727 (0.049) 0.783 (0.080) 0.813 (0.073) 0.726 (0.076) 0.784 (0.084) Endosteal diameter (cm) 0.459 (0.71) 0.416 (0.65) 0.442 (0.72) 0.427 (0.088) 0.409 (0.074) 0.421 (0.083) Cortical thickness (cm) 0.186 (0.027) 0.161 (0.024) 0.176 (0.029) 0.200 (0.028) 0.163 (0.027) 0.188 (0.032) Metacarpal index (mm/mm) 0.44 (0.06) 0.43 (0.07) 0.44 (0.06) 0.48 (0.08) 0.44 (0.07) 0.47 (0.

Comments are closed.